ArticleCureus2026
Evaluation of Symptomatic Improvement Following Functional Endoscopic Sinus Surgery in Chronic Rhinosinusitis: A Prospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic rhinosinusitis (CRS) is a prevalent inflammatory condition of the nasal cavity and paranasal sinuses characterized by symptoms persisting for more than 12 weeks, resulting in substantial impairment of quality of life. Functional endoscopic sinus surgery (FESS) is the established surgical treatment for patients who fail to respond to conservative medical management. Methods This prospective analytical study included 50 patients with medically refractory CRS who underwent FESS between April 2025 and March 2026. Four principal symptoms - nasal obstruction, facial pain, post-nasal drip, and anosmia - were scored preoperatively and at six months postoperatively using a four-point ordinal symptom severity scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). The Wilcoxon signed-rank test was used to compare preoperative and postoperative severity scores, with effect size calculated as r = Z/√N. Results The cohort comprised 32 males (64%) and 18 females (36%), with a mean age of 37.66 ± 13.95 years. Preoperative symptom prevalence was as follows: nasal obstruction in 92%, facial pain in 86%, anosmia in 74%, and post-nasal drip in 68%. Statistically significant reductions in mean severity scores were observed for nasal obstruction (2.40 to 1.66; p < 0.001, r = 0.99), facial pain (2.28 to 1.54; p < 0.001, r = 1.00), and post-nasal drip (1.54 to 1.24; p < 0.001, r = 1.00). Anosmia showed a non-significant trend toward improvement (1.58 to 1.44; p = 0.071, r = 0.47), with four patients demonstrating postoperative worsening. No patient experienced worsening of nasal obstruction, facial pain, or post-nasal drip. The complication rate was low, with minor bleeding in four (8%) patients and synechiae in three (6%) patients; no major complications were recorded. Conclusions FESS produced statistically significant and clinically meaningful improvements in nasal obstruction, facial pain, and post-nasal drip in patients with medically refractory CRS. Anosmia did not reach statistical significance, and its management in CRS warrants further investigation. The procedure was associated with a low complication rate, supporting its role as a safe and effective surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.